Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
Go back to Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer| ONCONOVA THERAPTCS (NYSE: ONTX) | Delayed: 15.79 +1.37 (9.50%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.42 | 52 Week High | $6.71 | |||
| Open | $15.44 | 52 Week Low | $0.32 | |||
| Day High | $15.91 | P/E | N/A | |||
| Day Low | $15.33 | EPS | $-2.36 | |||
| Volume | 6,830 | |||||
